Future developments in the management of malignant pleural mesothelioma

Expert Review of Anticancer Therapy

Volumn 9, Issue 4, 2009, Pages 453-467

  Zucali, Paolo Andrea ^a   De Vincenzo, Fabio ^a   Simonelli, Matteo ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Diagnosis; Malignant mesothelioma; Novel approach; Prognosis; Treatment

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CISPLATIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; FOLIC ACID ANTAGONIST; GEFITINIB; GEMCITABINE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MESOTHELIN; MITOMYCIN; NAVELBINE; OSTEOPONTIN; OXALIPLATIN; PEMETREXED; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RALTITREXED; SORAFENIB; SUNITINIB; THALIDOMIDE; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VATALANIB; VINBLASTINE; VORINOSTAT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; QUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE; TUMOR MARKER; TUMOR PROTEIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG EFFICACY; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HISTOPATHOLOGY; HUMAN; IMMUNOREACTIVITY; INTENSITY MODULATED RADIATION THERAPY; LEUKOCYTE COUNT; LUNG RESECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA BIOPSY; PLEURA MESOTHELIOMA; PLEURECTOMY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RADIATION DOSE; REVIEW; THORACOSCOPY; TREATMENT RESPONSE; ANIMAL; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; FORECASTING; MESOTHELIOMA; MOUSE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PLEURA TUMOR; RANDOMIZED CONTROLLED TRIAL; STATISTICS; THORAX SURGERY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; DRUG DELIVERY SYSTEMS; FORECASTING; GLUTAMATES; GUANINE; HUMANS; MESOTHELIOMA; MICE; MULTICENTER STUDIES AS TOPIC; NEOPLASM PROTEINS; NEOPLASM STAGING; PLEURAL NEOPLASMS; QUINAZOLINES; RADIOTHERAPY, INTENSITY-MODULATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; THORACIC SURGICAL PROCEDURES; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 67650290169     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.2     Document Type: Review

References (136)

1. Robinson BWS, Musk AW, Lake AR. Malignant mesothelioma. Lancet 366(9483), 397-408 (2005).
2. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin. Oncol. 29(1), 2-17 (2002).
3. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J. Clin. Oncol. 16(1), 145-152 (1998).
4. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113(3), 723-731 (1998).
5. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21(14), 2636-2644 (2003).
6. Van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 23(28), 6881-6889 (2005).
7. Zucali PA, Giaccone G. Biology and management of malignant pleural mesothelioma. Eur. J. Cancer 42(16), 2706-2714 (2006).
8. Lee AY, Raz DJ, He B, Jablons DM. Update on the molecular biology of malignant mesothelioma. Cancer 109(8), 1454-1461 (2007).
9. Sugarbaker DJ, Jaklitsch MT, Bueno R et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J. Thorac. Cardiovasc. Surg. 128(1), 138-146 (2004).
10. Ahamad A, Stevens CW, Smythe WR et al. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 55(3), 768-775 (2003).
11. Evans AL, Gleeson FV. Radiology in pleural disease: state of the art. Respirology 9(3), 300-312 (2004).
12. Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. Am. J. Roentgenol. 172(4), 1039-1047 (1999).
13. Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 115(2), 310-317 (1998).
14. Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 126(1), 11-16 (2003).
15. Erasmus JJ, Truong MT, Smythe WR et al. Integrated computed tomography - positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J. Thorac. Cardiovasc. Surg. 129(6), 1364-1370 (2005).
16. Truong MT, Marom EM, Erasmus JJ. Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging. J. Thorac. Imaging 21(2), 146-153 (2006).
17. Flores RM, Akhurst T, Gonen M et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 132(4), 763-768 (2006).
18. Whitaker D. The cytology of malignant mesothelioma. Cytopathology 11(3), 139-151 (2000).
19. Boutin C, Viallat JR, Van Zandwijk N et al. Activity of intrapleural recombinant γ-interferon in malignant mesothelioma. Cancer 67(8), 2033-2037 (1991).
20. Ordóñez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum. Pathol. 36(4), 372-380 (2005).
21. Gordon GJ, Jensen RV, Hsiao LL et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res. 62(17), 4963-4967 (2002).
22. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 14(1), 1-12 (1996).
23. Benamore RE, O'Doherty MJ, Entwisle JJ. Use of imaging in the management of malignant pleural mesothelioma. Clin. Radiol. 60(12), 1237-1247 (2005).
24. Van Meerbeeck JP, Boyer M. Consensus report: pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma. Lung Cancer 49(Suppl. 1), S123-S127 (2005).
25. Flores RM, Routledge T, Seshan VE et al. The impact of lymph node station on survival in 348 surgically resected malignant pleural mesothelioma (MPM) patients: implications for revision of the AJCC staging system. J. Thorac. Cardiovasc. Surg. 136(3), 605-610 (2008).
26. Grigoriu BD, Scherpereel A, Devos P et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin. Cancer Res. 13(10), 2928-2935 (2007).
27. Chang K, Pai LH, Pass H et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma, Am. J. Surg. Pathol. 16(3), 259-268 (1992).
28. Robinson BWS, Creaney J, Lake RA et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362(9396), 1612-1616 (2003).
29. Beyer HL, Geschwindt RD, Glover CL et al. MESOMARKTM: a potential test for malignant pleural mesothelioma. Clin. Chem. 53(4), 666-672 (2007).
30. Pass HI, Wali A, Tang N et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann. Thorac. Surg. 85(1), 265-272 (2008).
31. Sandhu H, Dehnen W, Roller M, Abel J, Unfried K. mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats. Carcinogenesis 21(5), 1023-1029 (2000).
32. Pass HI, Lott D, Leonardo F et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N. Engl. J. Med. 353(15), 1564-1573 (2005).
33. Flores RM, Pass HI, Seshan VE et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J. Thorac. Cardiovasc. Surg. 135(3), 620-626 (2008).
34. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O'Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55(9), 731-735 (2000).
35. Rusch VW, Rosenzweig K, Venkatraman E et al. A Phase II trial of surgical resection and adjuvant highdose hemithoracic radiation for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 122(4), 788-795 (2001).
36. Baldini EH. External beam radiation therapy for the treatment of pleural mesothelioma. Thorac. Surg. Clin. 14(4), 543-548 (2004).
37. Ahamad A, Stevens CW, Smythe WR et al. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J. 9(6), 476-484 (2003).
38. Forster KM, Smythe WR, Starkschall G et al. Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int. J. Radiat. Oncol. Biol. Phys. 55(3), 606-616 (2003).
39. Chan MF, Chui CS, Song Y et al. A novel radiation therapy technique for malignant pleural mesothelioma combining electrons with intensity-modulated photons. Radiother. Oncol. 79(2), 218-223 (2006).
40. Janne PA. Chemotherapy for malignant pleural mesothelioma. Clin. Lung Cancer 5(2), 98-106 (2003).
41. Steele JPC, Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann. Oncol. 16(3), 345-351 (2005).
42. Berghmans T, Paesmans M, Lalami Y et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38(2), 111-121 (2002).
43. Muers MF, Stephens RJ, Fisher P et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 371(9625), 1685-1694 (2008).
44. O'Brien MER, Watkins D, Ryan C et al. A randomized trial in malignant mesothelioma of early versus delayed chemotherapy in symptomatically stable patients: the MED trial. Ann. Oncol. 17(2), 270-275 (2006).
45. Byrne MJ, Davidson JA, Musk AW et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a Phase II study. J. Clin. Oncol. 17(1), 25-30 (1999).
46. Novak AK, Byrne M, Williamson R et al. Multicentre Phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br. J. Cancer 87(5), 491-496 (2002).
47. Favaretto AG, Aversa SML, Paccagnella A et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric Phase II study. Cancer 97(11), 2791-2797 (2003).
48. Ceresoli GL, Zucali PA, Favaretto AG et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J. Clin. Oncol. 24(9), 1443-1448 (2006).
49. Ceresoli GL, Castagneto B, Zucali PA et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two Phase II trials. Br. J. Cancer 99(1), 51-56 (2008).
50. Sorensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br. J. Cancer 99(1), 44-50 (2008).
51. Talbot DC, Margery J, Dabouis G et al. Phase II study of vinflunine in malignant pleural mesothelioma. J. Clin. Oncol. 5(30), 4751-4756 (2007).
52. Sorensen JB, Sørensen JB, Sundstrøm S, Perell K, Thielsen AK. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J. Thorac. Oncol. 2(2), 147-152 (2007).
53. Jassem J, Ramlau R, Santoro A et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J. Clin. Oncol. 26(10), 1698-1704 (2008).
54. Rusch VW. Pemetrexed and cisplatin for malignant pleutal mesothelioma: a new standard of care? J. Clin. Oncol. 21(14), 2629-2630 (2003).
55. Manegold C, Symanowski J, Gatzemeier U et al. Second-line (poststudy) chemotherapy received by patients treated in the Phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann. Oncol. 16(6), 923-927 (2005).
56. Serke M, Xanthopoulos A, Bauer T. Second line chemotherapy in malignant pleural mesothelioma with oxaliplatin/gemcitabine. Ann. Oncol. 17(Suppl. 9), 231a (2006).
57. Zucali PA, Ceresoli GL, Garassino I et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 112(7), 1555-1561 (2008).
58. Stebbing J, Powles T, McPherson K et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 63(1), 94-97 (2009).
59. Jackman D, Kindler HL, Yeap BY et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 113(4), 808-814 (2008).
60. Zucali PA, Gregorc V, Ceresoli GL et al. NGR-hTNF, a novel vascular targeting agent, as second-line therapy in mpm: preliminary results of a multicenter Phase II trial. Presented at: The 9th International Conference of the IMIG. Amsterdam, The Netherlands, 25-27 September 2008.
61. Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J. Thorac. Cardiovasc. Surg. 117(1) 54-65 (1999).
62. Weder W, Kestenholz P, Taverna C et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J. Clin. Oncol. 22(17), 3451-3457 (2004).
63. Flores RM, Krug LM, Rosenzweig KE et al. Induction chemotherapy, Extrapleural pneumonectomy, and postoperative high dose radiotherapy for locally advanced malignant pleural mesothelioma: a Phase II trial. J. Thorac. Oncol. 1(4), 289-295 (2006).
64. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J. Clin. Oncol. 19(1), 265-272 (2001).
65. Fennell D, Steele J, Sheaff M et al. Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage. Lung Cancer 49(Suppl. 2), S220 (2005) (Abstract P-397).
66. Francart J, Legrand C, Sylvester R, Van Glabbeke M, van Meerbeeck JP, Robert A. Progression-free survival rate as primary endpoint for Phase II cancer clinical trials: application to mesothelioma. The EORTC Lung Cancer Group. J. Clin. Oncol. 24(19), 3007-3012 (2006).
67. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann. Oncol. 15(2), 257-260 (2004).
68. Armato SG 3rd, Oxnard GR, MacMahon H et al. Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med. Phys. 31(5), 1105-1115 (2004).
69. Armato SG 3rd, Ogarek JL, Starkey A et al. Variability in mesothelioma tumor response classification. Am. J. Roentgenol. 186(4), 1000-1006 (2006).
70. Armato SG 3rd, Oxnard GR, Kocherginsky M, Vogelzang NJ, Kindler HL, MacMahon H. Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans. Acad. Radiol. 12(10), 1301-1309 (2005).
71. Oxnard GR, Armato SG 3rd, Kindler HL. Modeling of mesothelioma growth demonstrates weakness of current response criteria. Lung Cancer 52(2), 141-148 (2006).
72. Atri M. New technologies and directed agents for applications of cancer imaging. J. Clin. Oncol. 24(20), 3299-3308 (2006).
73. 18F]fluorodeoxyglucose. J. Clin. Oncol. 24(28), 4587-4593 (2006).
74. Weber WA. Positron emission tomography as an imaging biomarker. J. Clin. Oncol. 24(20), 3282-3292 (2006).
75. Ceresoli GL, Chiti A, Gianoncelli L et al. Early response evaluation in MPM by total glycolitic volume analysis of serial FDG-PET scans. Presented at: The 9th International Conference of the IMIG. Amsterdam, The Netherlands, 25-27 September 2008.
76. Grigoriu BD, Scherpereel A, Devos P et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin. Cancer Res. 13(10), 2928-2935 (2007).
77. Schneider J, Hoffmann H, Dienemann H, Herth F, Meister M, Muley T. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J. Thorac. Oncol. 3(11), 1317-1324 (2008).
78. Roe OD, Creaney J, Lundgren S et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case - control study. Lung Cancer 61(2), 235-243 (2008).
79. Klabatsa A, Sheaff MT, Steele JP, Evans MT, Rudd RM, Fennell DA. Expression and prognostic significance of hypoxia-inducible factor 1α (HIF-1α) in malignant pleural mesothelioma (MPM). Lung Cancer 51(1), 53-59 (2006).
80. Kokturk N, Firat P, Akay H et al. Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma. Lung Cancer 50(2), 189-198 (2005).
81. Strizzi L, Catalano A, Vianale G et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J. Pathol. 193(4), 468-475 (2001).
82. Ohta Y, Shridhar V, Bright RK et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer 81(1), 54-61 (1999).
83. Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF β expression. J. Pathol. 189(1), 72-78 (1999).
84. Gordon GJ, Jensen RV, Hsiao LL et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J. Natl Cancer Inst. 95(8), 598-605 (2003).
85. Gordon GJ, Rockwell GN, Godfrey PA et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin. Cancer Res. 11(12), 4406-4414 (2005).
86. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest. 115(6), 1503-1521 (2005).
87. Lopez-Rios F, Chuai S, Flores R et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 66(6), 2970-2979 (2006).
88. Cacciotti P, Barbone D, Porta C et al. SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res. 65(12), 5256-5262 (2005).
89. Ramos-Nino ME, Vianale G, Sabo-Attwood T et al. Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. Mol. Cancer Ther. 4(5), 835-842 (2005).
90. Pespeni MH, Hodnett M, Abayasiriwardana KS et al. Sensitization of mesothelioma cells to tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt pathway. Cancer Res. 67(6), 2865-2871 (2007).
91. Altomare DA, You H, Xiao GH et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24(40), 6080-6089 (2005).
92. Fennell DA, Rudd RM. Defective coreapoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol. 5(6), 354-362 (2004).
93. Govindan R, Kratzke RA, Herndon JE 2nd et al.; Cancer and Leukemia Group B (CALGB 30101); Gefitinib in patients with malignant mesothelioma: a Phase II study by the Cancer and Leukemia Group B. Clin. Cancer Res. 11(6), 2300-2304 (2005).
94. Lee CW, Anderson H, Martins H et al. A Phase II trial of gefitinib in patients with malignant pleural mesothelioma. Presented at: 44th ASCO Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
95. Garland LL, Rankin C, Gandara DR et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J. Clin. Oncol. 25(17), 2406-2413 (2007).
96. Cortese JF, Gowda AL, Wali A, Eliason JF, Pass HI, Everson RB. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int. J. Cancer 118(2), 521-522 (2006).
97. Destro A, Ceresoli GL, Falleni M et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinicopathological correlations. Lung Cancer 51(2), 207-215 (2006).
98. Langerak A, van der Linden-van Beurden CA, Versnel MA. Regulation of differential expression of platelet-derived growth factor α- and β-receptor mRNA in normal and malignant human mesothelial cell lines. Biochim. Biophys. Acta 1305(1-2), 63-70 (1996).
99. Dorai T, Kobayashi H, Holland JF, Ohnuma T. Modulation of platelet-derived growth factor-β mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme. Mol. Pharmacol. 46(3), 437-444 (1994).
100. Bertino P, Piccardi F, Porta C et al. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenogtafts. Clin. Cancer Res. 14(2), 541-548 (2008).
101. Bertino P, Porta C, Barbone D et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 62(8), 690-695 (2007).
102. Dowell J, Kindler HL. Anti-angiogenic therapies for mesothelioma. Hematol. Oncol. Clin. N. Am. 19(6), 1137-1146 (2005).
103. Cacciotti P, Strizzi L, Vianale G et al. The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. Am. J. Respir. Cell. Mol. Biol. 26(2), 189-193 (2002).
104. Linder C, Linder S, Munck-Wikland E, Strander H. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res. 18(3B), 2063-2068 (1998).
105. Edwards JG, Swinson DE, Jones JL, Muller S, Waller DA, O'Byrne KJ. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 124(5), 1916-1923 (2003).
106. Jahan TM, Gu L, Wang X et al. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a Phase II study by the Cancer and Leukemia Group B (CALGB 30107). Presented at: 42nd ASCO Annual Meeting. Atlanta, GA, USA, 2-6 June 2006.
107. Baas P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, van Zandwijk N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 48(2), 291-296 (2005).
108. Janne PA, Wang XF, Krug LM et al. Sorafenib in malignant mesothelioma: a Phase II trial of the Cancer and Leukemia Group B (CALGB 30307). Presented at: 43rd ASCO Annual Meeting. Chicago, IL, USA, 1-4 June 2007.
109. Nowak AK, Millward MJ, Francis R et al. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). Presented at: 44th ASCO Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
110. Karrison T, Kindler HL, Gandara DR et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized Phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients (pts) with malignant mesothelioma. Presented at: 43rd ASCO Annual Meeting. Chicago, IL, USA, 1-4 June 2007.
111. Ceresoli GL, Zucali PA, De Vincenzo F et al. Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma. Presented at: The 9th International Conference of the IMIG. Amsterdam, The Netherlands, 25-27 September 2008.
112. Curnis F, Arrigoni G, Sacchi A et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 62(3), 867-874 (2002).
113. Singhal S, Wiewrodt R, Malden LD et al. Gene expression profiling of malignant mesothelioma. Clin. Cancer Res. 9(8), 3080-3097 (2003).
114. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007).
115. Motzer RJ, Escudier B, Oudard S et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter Phase-III study. Presented at: 44th ASCO Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
116. Mazzone M, Comoglio PM. The Met pathway: master switch and drug target in cancer progression. FASEB J. 20(10), 1611-1621 (2006).
117. Tolnay E, Kuhnen C, Wiethege T, Konig JE, Voss B, Muller KM. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J. Cancer Res. Clin. Oncol. 124(6), 291-296 (1998).
118. Cacciotti P, Libener R, Betta P et al. SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc. Natl Acad. Sci. USA 98, 12032-12037 (2001).
119. Tsao AT, He D, Saigal B et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol. Cancer Ther. 6(7), 1962-1972 (2007).
120. Cao XX, Mohuiddin I, Ece F, McConkey DJ, Smythe WR. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am. J. Respir. Cell. Mol. Biol. 25(5), 562-568 (2001).
121. Krug LM, Curley T, Schwartz L et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin. Lung Cancer 7(4), 257-261 (2006).
122. Cusack JC Jr, Liu R, Houston M et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res. 61(9), 3535-3540 (2001).
123. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol. Cancer Ther. 2(9), 835-843 (2003).
124. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Res. 64(15), 5036-5043 (2004).
125. Sartore-Bianchi A, Gasparri F, Galvani A et al. Bortezomib inhibits nuclear factor-κB dependent survival and has potent in vivo activity in mesothelioma. Clin. Cancer Res. 13(19), 5942-5951 (2007).
126. Gordon GJ, Mani M, Maulik G et al. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother. Pharmacol. 61(4), 549-558 (2008).
127. Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod. Pathol. 21(6), 742-747 (2008).
128. Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 23(7), 1127-1130 (2002).
129. Whitson BA, Kratzke RA. Molecular pathways in malignant pleural mesothelioma. Cancer Lett. 239(2), 183-189 (2006).
130. Lopez-Rios F, Chuai S, Flores R et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 66(6), 2970-2979 (2006).
131. Kobayashi N, Toyooka S, Yanai H et al. Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer 62(1), 120-125 (2008),
132. Davidson B, Reich R, Lazarovici P et al. Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer 44(2), 159-165 (2004).
133. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 44(1), 46-53 (2008).
134. Hassan R, Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin. Cancer Res. 13(23), 7166-7171 (2007).
135. Hassan R, Ebel W, Routhier EL et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 7, 20 (2007).
136. Leland P, Raines RT. Cancer chemotherapy - ribonucleases to the rescue. Chem. Biol. 8(5), 405-413 (2001).